KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Research & Development (2016 - 2025)

Historic Research & Development for Neogenomics (NEO) over the last 15 years, with Q3 2025 value amounting to $8.7 million.

  • Neogenomics' Research & Development rose 1314.42% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 1830.66%. This contributed to the annual value of $31.2 million for FY2024, which is 1409.79% up from last year.
  • Per Neogenomics' latest filing, its Research & Development stood at $8.7 million for Q3 2025, which was up 1314.42% from $9.0 million recorded in Q2 2025.
  • Neogenomics' Research & Development's 5-year high stood at $10.2 million during Q1 2025, with a 5-year trough of $2.5 million in Q1 2021.
  • Over the past 5 years, Neogenomics' median Research & Development value was $7.6 million (recorded in 2024), while the average stood at $7.3 million.
  • In the last 5 years, Neogenomics' Research & Development skyrocketed by 30538.1% in 2021 and then tumbled by 2772.16% in 2023.
  • Neogenomics' Research & Development (Quarter) stood at $8.5 million in 2021, then dropped by 21.59% to $6.7 million in 2022, then increased by 6.77% to $7.1 million in 2023, then rose by 11.81% to $8.0 million in 2024, then grew by 9.1% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $9.0 million for Q2 2025, and $10.2 million during Q1 2025.